Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cardiol Therapeutics (CRDL)

Cardiol Therapeutics (CRDL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ PR Newswire - Thu May 14, 6:27AM CDT

TORONTO , May 14, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association PR Newswire - Thu May 7, 6:27AM CDT

TORONTO, ON , May 7, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association PR Newswire - Thu May 7, 6:27AM CDT

TORONTO, ON , May 7, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program PR Newswire - Tue Apr 28, 6:27AM CDT

TORONTO , April 28, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program PR Newswire - Tue Apr 28, 6:27AM CDT

TORONTO , April 28, 2026 /CNW/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a late-stage life sciences company advancing anti-inflammatory and...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart Newsfile - Tue Apr 14, 6:32AM CDT

Toronto, Ontario--(Newsfile Corp. - April 14, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics Announces Year-End 2025 Update on Operations Newsfile - Wed Apr 1, 6:38AM CDT

Initiated pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis and surpassed 50% patient enrollment, with full enrollment expected in Q2 2026.Reported positive Phase II ARCHER data...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference Newsfile - Wed Feb 25, 6:34AM CST

Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure Newsfile - Tue Feb 10, 6:34AM CST

Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million Newsfile - Fri Jan 23, 8:24AM CST

Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development...

CRDL.TO : 1.57 (-2.48%)
CRDL : 1.1100 (-3.48%)

Barchart Exclusives

Tesla Sales in China Are Popping, But That Means Nothing If You Can’t Stomach TSLA Stock’s Absurd P/E Ratio Barchart - 45 minutes ago
Tesla China sales jumped almost 40% in May as its FSD software rolled out globally. Here's why TSLA stock still belongs on your watch list now. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.